Abstract:Introduction Primary ciliary dyskinesia (PCD) is a genetic disease caused by mutations that alter cilia beating, including in the respiratory airways, resulting in impaired mucus clearance and severe morbidity as well as increased mortality. We hypothesized that we could restore bronchial cilia beating with genetically corrected iPSC differentiated into bronchial progenitors. Methods Our project aims to assess the ability of a corrected iPSC line to functionally repair pathological models in vitro. We generated a PCD patient iPSC line reprogrammed using Sendai viruses, and the corresponding CRISPR/Cas9 corrected cell line, as well a wild-type iPSC line and its CRISPR/Cas9 mutated counterpart. We also generated a GFP-iPSC line expressing the fluorescent GFP protein under the human elongation factor 1 alpha promoter (EF1a), allowing us to study the engraftment ability of GFP bronchial stem cells on a control epithelium model. To assess the efficiency of different bronchial progenitors to engraft a bronchial epithelium, we used our previously published air–liquid interface bronchial epithelium model (iALI). Results One main issue is to identify the competent cell type for regeneration of the adult bronchial epithelium. Indeed, there are several cell types constituting the bronchial epithelium, as well as several developmentally bronchial progenitor cells that could be considered. Our iALI differentiation process mimics the embryonic development and thus the iALI model may provide any cell type from the definitive endoderm to the mature bronchial epithelium. Our results suggest that lung progenitors at the ventralized anterior foregut endoderm stage, could be the most efficient cells for engraftment. Besides, their self-renewal ability and their capacity to differentiate into the different cell type spectrum of the bronchial epithelium are promising for the development of a long-term and efficient therapy. The second issue for bronchial epithelium cell replacement would be to determine the best strategy to erode the bronchi prior to cell therapy. Such an erosion is considered necessary to promote cell engraftment because of the barrier function of the intact bronchial epithelium and the lack of selection advantage from the corrected cells. To this end, we compared mechanical, chemical and enzymatic erosion strategies on the iALI model. Our results suggest a better efficiency with enzymatic erosion, showing a homogeneous detachment of the cells and a better engraftment of cells from the GFP-iPSC line. Conclusion In conclusion, engraftment of corrected lung progenitors to enzymatically eroded bronchial epithelium seems to be a promising therapeutic strategy to treat PCD. Future experiments will refine the best condition regarding enzymatic solution (concentration, time exposure) and graft cell number to assure functional recovery of the mucociliary clearance.

Engraftment of wild-type alveolar type II epithelial cells in surfactant protein C deficient mice

Increased and Prolonged Pulmonary Fibrosis in Surfactant Protein C-Deficient Mice Following Intratracheal Bleomycin

A novel human fetal lung-derived alveolar organoid model reveals mechanisms of surfactant protein C maturation relevant to interstitial lung disease

Humanized L184Q Mutated Surfactant Protein C Gene Alters Alveolar Type 2 Epithelial Cell Fate

Lung cell transplantation for pulmonary fibrosis

A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency

Airway derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD

Human pluripotent stem cell modeling of alveolar type 2 cell dysfunction caused by ABCA3 mutations

Combined cellular and gene therapy to treat primary ciliary dyskinesia

Targeted pre-conditioning and cell transplantation in the murine lower respiratory tract

Induced pluripotent stem cell-derived lung alveolar epithelial type II cells reduce damage in bleomycin-induced lung fibrosis

Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency

Bone Marrow-Derived VSELs Engraft as Lung Epithelial Progenitor Cells after Bleomycin-Induced Lung Injury

Isolation and Characterization of Alveolar Epithelial Type II Cells Derived from Mouse Embryonic Stem Cells

FGFR2 Is Required for AEC2 Homeostasis and Survival after Bleomycin-induced Lung Injury

Engraftment of bone marrow stromal cells in lipopolysaccharide-injured mouse lungs

Clinical Characteristics and Genetic Analysis of Interstitial Lung Disease in Chinese Children (Genes and Interstitial Lung Disease)

Neonatal Type II Alveolar Epithelial Cell Transplant Facilitates Lung Reparation in Piglets With Acute Lung Injury and Extracorporeal Life Support.

Lung inflammation and interstitial fibrosis by targeted alveolar epithelial type I cell death

Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis.

Generation of Pulmonary Endothelial Progenitor Cells for Cell-based Therapy Using Interspecies Mouse-Rat Chimeras